NantKwest launches clinical trial for natural killer cells

NantKwest Inc. (NSDQ:NK) said yesterday that the FDA approved an Investigational New Drug Application for its natural killer cell therapy phase I clinical study. The company is evaluating its genetically engineered, allogenic natural killer cell therapy in patients with cancer.

The study, which NantKwest touts as the 1st of its kind, will determine the safety of natural killer cell monotherapy given intravenously once a week in as many as 16 patients with metastatic or locally advanced solid tumors.

Get the full story at our sister site, Drug Delivery Business News.

The post NantKwest launches clinical trial for natural killer cells appeared first on MassDevice.

from MassDevice http://ift.tt/2jmtiK8